Welcome to our dedicated page for Sight Sciences news (Ticker: SGHT), a resource for investors and traders seeking the latest updates and insights on Sight Sciences stock.
Sight Sciences, Inc. (Nasdaq: SGHT) is an eyecare technology company that regularly issues news about its interventional glaucoma and dry eye businesses. As a manufacturer of ophthalmic medical devices, the company provides updates on its OMNI® and SION® glaucoma technologies and its TearCare® System for evaporative dry eye disease due to meibomian gland disease.
News for SGHT often includes quarterly and annual financial results, revenue guidance updates, and commentary on operating expenses and restructuring plans. The company uses press releases and Form 8-K filings to report results of operations, changes to loan agreements, and targeted cost-reduction initiatives designed to align its operating structure with long-term objectives.
Clinical and scientific developments are another recurring theme. Sight Sciences highlights peer-reviewed publications, systematic reviews, and meta-analyses evaluating the OMNI Surgical System in primary open-angle glaucoma, including standalone and cataract-combination procedures. It also reports on randomized controlled trials and guideline recognition related to the TearCare System in dry eye disease and meibomian gland disease.
Coverage decisions and reimbursement milestones frequently appear in the company’s announcements. Examples include jurisdiction-wide pricing for CPT® code 0563T, which describes the TearCare procedure, established by Medicare Administrative Contractors, and expanded coverage policies from commercial insurers for implant-free, minimally invasive glaucoma surgery procedures that include OMNI.
Corporate governance and leadership changes are also disclosed, such as executive promotions, board resignations, and new officer appointments. Investors following SGHT news can expect a mix of financial updates, clinical evidence summaries, reimbursement developments, and corporate actions related to its interventional eye care technologies.
Sight Sciences (Nasdaq: SGHT) has officially launched the Ergo-Series of the OMNI® Surgical System in the U.S., aimed at enhancing minimally invasive, implant-free glaucoma procedures.
The new features include:
- Improved Handle Ergonomics: Enhances precise control for surgeons.
- Simplified Viscoelastic Preparation: Removable luer connector for better clearance during surgery.
- New Cannula Tip Design: Enables gentler access to Schlemm's canal.
The Ergo-Series maintains the same therapeutic functionality as previous models, enabling effective treatment for patients with primary open-angle glaucoma.
Sight Sciences, Inc. (Nasdaq: SGHT) will report its financial results for the fourth quarter and full year ending December 31, 2022, on March 13, 2023, after market close. The management will discuss the results in a conference call at 1:30 PM PT / 4:30 PM ET. Investors can listen live or access a replay on the company's website for at least 90 days. Sight Sciences focuses on innovative eye care solutions, including the OMNI® Surgical System for glaucoma and the TearCare® System for dry eye disease. These products aim to improve patient outcomes through minimally invasive techniques, addressing significant health issues in eye care.
Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology firm, announced its participation in the Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference in New York on March 1, 2023, at 3:30 PM ET. The company will host a fireside chat, which will be accessible live and archived on its website’s 'Investors' section. Sight Sciences focuses on innovative, minimally invasive solutions for prevalent eye diseases, including the OMNI® Surgical System for glaucoma and the TearCare® System for dry eye disease. These advancements aim to enhance patient care and replace outdated treatment methods.
Sight Sciences announced that over 1,000 eye care practices have integrated its TearCare® System, aimed at treating dry eye disease due to meibomian gland dysfunction (MGD). This FDA-cleared system provides localized heat therapy in conjunction with manual gland expression. Since its launch in 2019, the system has gained traction among practitioners, supported by favorable clinical trial results, including the ongoing SAHARA study designed to compare its efficacy with traditional treatments. The 1,000th installation was at Total Eye Care in Long Island, reflecting a growing acceptance and confidence in the TearCare® System.
Sight Sciences (Nasdaq: SGHT) announced preliminary financial results for Q4 and full year 2022, highlighting a projected 40% increase in Q4 revenue, estimated between $20.4 million and $20.6 million. Full year revenue is expected to be $71.2 million to $71.4 million, marking a 46% year-over-year growth. Surgical Glaucoma and Dry Eye product revenues showed significant growth, with Dry Eye revenues increasing by 134% compared to the prior year. Additionally, the company announced a CFO transition, with interim leadership stepping in as the search for a replacement begins.
Verana Health and Sight Sciences have initiated a research collaboration to enhance treatment outcomes for patients with primary open-angle glaucoma (POAG). This partnership will utilize Verana's Qdata Glaucoma real-world data module, which encompasses over 341,000 MIGS records from more than 5 million patients with extensive follow-up data. The OMNI Surgical System, a minimally invasive solution for lowering intraocular pressure, will be evaluated for its long-term efficacy and safety. POAG currently affects 2.7 million Americans, making this research crucial.
Sight Sciences, Inc. (Nasdaq: SGHT) presented data at the 2022 American Academy of Optometry showing significant improvements in meibomian gland function and dry eye symptoms using the TearCare® System. A study of 78 patients indicated a 63% improvement in gland function and a 44% reduction in dry eye symptoms over 12 months. Results demonstrated sustained efficacy, with symptom relief lasting up to 18 months post-treatment. The findings suggest potential for broader adoption of TearCare® in treating meibomian gland disease, addressing patient compliance with traditional eye drop regimens.
Sight Sciences, an eyecare technology company, announced its participation in the Piper Sandler 34th Annual Healthcare Conference in New York on November 30, 2022, at 11:30am ET. The company aims to transform patient care with innovative solutions for prevalent eye diseases. Interested individuals can access a live and archived webcast of the fireside chat via the company's website. Sight Sciences focuses on minimally invasive treatments, including the OMNI Surgical System for glaucoma and the TearCare System for dry eye disease.
Sight Sciences reported strong financial results for Q3 2022, with total revenue of $18.7 million, marking a 43% increase year-over-year and an 8% rise from Q2 2022. The gross margin stood at 84%. The company increased the number of facilities using its OMNI Surgical System to 913 and the TearCare System to 881. Surgical Glaucoma revenue rose 37% year-over-year, while Dry Eye revenue surged 145%. Despite a net loss of $22.2 million, the outlook for 2022 revenue is projected between $70 million and $72 million, reflecting 43% to 47% growth.
Sight Sciences announced the publication of clinical data demonstrating the safety and effectiveness of the OMNI Surgical System in treating pseudophakic glaucoma patients. The study, published in International Ophthalmology, highlights the potential of OMNI as a minimally invasive, implant-free solution for patients whose intraocular pressure (IOP) is no longer controlled by existing treatments. Follow-ups of 3 to 42 months revealed that most participants regained IOP control, emphasizing OMNI's role in managing glaucoma throughout its progression.